1 Priority Biocidal, LLC – Trademark Portfolio

Entity Type: 16

1 Priority Biocidal, LLC holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 7 (Machinery) — 4 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include BIOSPRAY. The owner is based in Fort Worth, TX.

2410 Gravel Drive

Fort Worth, TX 76118

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

1 Priority Biocidal, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

7
Machinery (4 filings)

Machines and machine tools; motors and engines; machine coupling and transmission components

5
Pharmaceuticals (3 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does 1 Priority Biocidal, LLC have?

1 Priority Biocidal, LLC has 4 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 abandoned, 2 cancelled.

What trademark classes does 1 Priority Biocidal, LLC file in?

1 Priority Biocidal, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 7 (Machinery), Class 5 (Pharmaceuticals). Class 7 covers machines and machine tools; motors and engines; machine coupling and transmission components.

What are 1 Priority Biocidal, LLC's most well-known trademarks?

1 Priority Biocidal, LLC's registered trademark portfolio includes well-known marks such as BIOSPRAY. These are among 1 currently registered trademark in the portfolio.

What is 1 Priority Biocidal, LLC's trademark registration success rate?

1 Priority Biocidal, LLC has a 25% trademark registration rate, with 1 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.